Anastrozole Sandoz

Anastrozole Sandoz





Zuellig Pharma
Concise Prescribing Info
Advanced breast cancer in post-menopausal women. Adjuvant treatment of post-menopausal women w/ hormone receptor positive early invasive breast cancer & in early breast cancer hormone receptor positive post-menopausal woman who have received 2-3 yr of adjuvant tamoxifen.
Dosage/Direction for Use
Adult including elderly 1 mg once daily. Postmenopausal women w/ hormone receptor-positive early invasive breast cancer Recommended duration of adjuvant endocrine treatment: 5 yr.
May be taken with or without food.
Special Precautions
Do not use in pre-menopausal women. Avoid concomitant use w/ tamoxifen or estrogen-containing therapies. Increased risk of fracture due to reduction in bone mineral density. Carefully monitor & initiate treatment or prophylaxis for osteoporosis. Moderate or severe hepatic & severe renal impairment. Do not use in boys w/ growth hormone deficiency in addition to growth hormone treatment. May impair the ability to drive & use machinery. Childn & adolescents.
Adverse Reactions
Headache; hot flushes; nausea; rash; arthralgia/joint stiffness, arthritis, osteoporosis; asthenia. Anorexia; somnolence, carpal tunnel syndrome; diarrhea, vomiting; increases in alkaline phosphatase, alanine aminotransferase & aspartate aminotransferase; hair thinning (alopecia), allergic reactions; bone pain, myalgia; vag dryness & bleeding.
Drug Interactions
Pharmacologic action may be diminished w/ tamoxifen or estrogen-containing therapies.
ATC Classification
L02BG03 - anastrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Anastrozole Sandoz FC tab 1 mg
2 × 14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in